Ads
related to: acid peptic disease management- Dosing
Find Out More About Our
Flexible Dosing Options.
- Downloadable Resources
Browse Patient Resources
For Your Patients.
- What is PCAB
Learn The Novel Mechanism
Of Action Behind PCABs.
- Request a Rep
Reach Out With Questions
Or Comments!
- Dosing
Search results
Results From The WOW.Com Content Network
Mucosal disruption in acid peptic disease patients can be caused by infection, barrier disruption, or gastric acid hypersecretion.Acid peptic diseases can arise due to various risk factors such as Helicobacter pylori infection, alcoholism, tobacco use, cocaine and amphetamine use, nonsteroidal anti-inflammatory drug use (NSAIDs), fasting, Zollinger-Ellison syndrome, angiogenesis inhibitor ...
Peptic ulcers are present in around 4% of the population. [1] New ulcers were found in around 87.4 million people worldwide during 2015. [5] About 10% of people develop a peptic ulcer at some point in their life. [9] Peptic ulcers resulted in 267,500 deaths in 2015, down from 327,000 in 1990.
There are several classes of drugs for acid-related disorders, such as dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD), or laryngopharyngeal reflux. The World Health Organization gives drugs in these classes the categorization code ATC code A02 .
Truncal vagotomy is a treatment option for chronic duodenal ulcers. [5] [6] It was once considered the gold standard, but is now usually reserved for patients who have failed the first-line "triple therapy" against Helicobacter pylori infection: two antibiotics (clarithromycin and amoxicillin or metronidazole) and a proton pump inhibitor (e.g., omeprazole).
The proton pump is the terminal stage in gastric acid secretion, being directly responsible for secreting H + ions into the gastric lumen, making it an ideal target for inhibiting acid secretion. [ citation needed ] Because the H,K-ATPase is the final step of acid secretion, an inhibitor of this enzyme is more effective than receptor ...
ATC code A02 Drugs for acid related disorders is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.